Home › Products › Oncology › Rahika 150mg Tablet
Rahika 150mg Tablet
Salt Composition: CAPMATINIB
- Manufacturer: NOVARTIS INDIA LTD
- Pack Size: 12 TABLET(s) IN A STRIP
- Dosage Form: TABLET
- Strength: 150MG
- Prescription Required
- Storage: Store at 20°C to 25°C Protect the medicine from light and excessive moisture. Keep the medicine out of reach of children and pets If you forgot to take the tablet, take your next dose at the scheduled time. Do not take a double dose to make up for a forgotten dose.
₹14682.00₹15454.69
Inclusive of all taxes
Product Introduction
Rahika 150mg tablet contains the active ingredient Capmatinib. It is an anti-cancer medicine that belongs to the class of medications called protein kinase inhibitors. It is used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other body parts or is caused by a mutation in the gene that encodes the MET enzyme.
Do not take this medicine if you are allergic to Rahika 150mg tablet or any of its ingredients. Inform your physician if you have or have ever had lung or breathing problems other than your lung cancer, liver problems, or pancreatic problems. Inform your physician if you experience any symptoms of an allergic reaction, including rash, hives, fever, difficulty breathing, or low blood pressure.
This medicine is not recommended for children and adolescents below 18 years of age. Avoid pregnancy and breastfeeding during treatment. Use effective contraception to prevent pregnancy.
The common side effects of Rahika 150mg tablet are swelling in the face and body, nausea, tiredness, vomiting, shortness of breath, and decreased appetite.
Uses
Non-small cell lung cancer (NSCLC)
How it works
Rahika 150mg tablet is a kinase inhibitor that targets mesenchymal-epithelial transition (MET). It works by blocking the action of this abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.
How to Use
It is an orally available prescription drug. Your doctor will decide the dose and duration of Rahika 150mg tablet based on the disease condition and other factors. Always take this medicine as prescribed by your doctor. Take the tablet with or without food. Do not break, chew, crush, or break the tablet. Swallow the whole tablet with water.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Common Swelling in the face, and body Decrease in appetite Nausea Cough Fatigue Serious Vomiting Liver injury Muscle pain Shortness of breath Lung infection Respiratory disease
Expert Tips
Limit direct exposure to the sun or artificial ultraviolet (UV) light while using this medicine. Use sunscreen, wear sunglasses and protective clothing while you are going outdoors, and for at least 7 days after you stop taking it. Report immediately to your doctor if you have abdominal pain. This medicine may cause birth defects if either partner is using it during conception or pregnancy. If you are a female patient with reproductive potential, use an effective form of birth control during the treatment and for 1 week after the last dose. Male patients with female partners should use an effective form of birth control during treatment and for at least 1 week after the last dose. Do not breastfeed while using this medicine and for at least 1 week after your last dose. Your doctor may do lab tests to check the therapy's effectiveness or monitor the unwanted side effects.
References
- Capmatinib Tablets, PIL.; 2022. Accessed May 2, 2023. https://www.ema.europa.eu/en/documents/product-information/tabrecta-epar-product-information_en.pdf
- TABRECTATM - Capmatinib Tablets.; 2020. Accessed May 2, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf
- Vansteenkiste JF, Van De Kerkhove C, Wauters E, Van Mol P. Capmatinib for the treatment of non-small cell lung cancer. Expert Review of Anticancer Therapy . 2019;19(8):659-671. doi: https://doi.org/10.1080/14737140.2019.1643239
- Choi W, Park SY, Lee Y, et al. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification. Cancer Research and Treatment . Published online January 29, 2021. doi: https://doi.org/10.4143/crt.2020.1331
Safety Advice
Pregnancy: unsafe Do not take Rahika 150mg tablet if you are pregnant because this may harm the unborn baby. Inform your physician if you are pregnant, suspecting, or planning to get pregnant during the treatment. Use effective contraception during the treatment and for 7 days after your last dose.
Lungs: unsafe Rahika 150mg tablet should be cautiously administered in patients with lung problems other than lung cancer. Inform your physician if you have any lung diseases before initiating the therapy.
Breastfeeding: unsafe Breastfeeding is not recommended in patients taking Rahika 150mg tablet because the medicine passes into the breast milk in small amounts and may harm your baby. Do not breastfeed during the treatment.
Disclaimer
The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.